A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial
Open Access
Abstract
BACKGROUND: To explore the role of bevacizumab and a chemotherapy‐free approach, the authors evaluated the combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and bevacizumab (HA) with the addition of paclitaxel after progression (HA‐HAT) as first‐line treatment for patients with human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer.METHODS: In a noncomparative phase 2 trial, patients were randomized between HAT and HA‐HAT. The primary endpoint was the progression‐free rate at 1 year (1‐year PFR). In the HA‐HAT group, progression‐free survival (PFS) was separately established for HA (PFS1) and HAT (PFS2).RESULTS: Eighty‐four patients received HAT (n = 39) or HA‐HAT (n = 45). The 1‐year PFR was 74.4% (95% confidence interval [CI], 61.8%‐89.4%) and 62.2% (95% CI, 49.6%‐89.4%) in the HAT and HA‐HAT arms, respectively. The median PFS was 19.8 months (95% CI, 14.9‐25.6 months) in the HAT arm and 19.6 months (95% CI, 12.0‐32.0 months) in the HA‐HAT arm. In the HA‐HAT arm, the median PFS1 was 10.4 months (95% CI, 6.2‐15.0 months), and the median PFS2 was 8.2 months (95% CI, 7.0‐12.6 months). The number and severity of adverse events were comparable between the arms.CONCLUSIONS: Both HAT and HA‐HAT have promising activity in patients with HER2‐positive metastatic breast cancer. In particular, starting with only targeted agents and delaying chemotherapy is worth further exploration. Cancer 2016;122:2961‐2970. © 2016 American Cancer Society.Keywords
Funding Information
- Dutch Cancer Society (KWF) (EMCR2009-4398)
- Roche Netherlands BV
This publication has 30 references indexed in Scilit:
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX TrialClinical Breast Cancer, 2011
- Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized TrialThe Oncologist, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly ScheduleJournal of Clinical Oncology, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001